The early PET data provides a strong proof-of-mechanism signal across a third indication, increasing the probability of success for intranasal foralumab's platform potential. However, with only two patients reported, the data is preliminary. Monitor for enrollment updates and additional patient data from the Phase 2 MSA trial, as well as upcoming data readouts from the ongoing Phase 2a trial in non-active secondary progressive MS.
Price Chart
Executive Summary
Tiziana Life Sciences reported initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in a Phase 2 clinical trial treated with intranasal foralumab. The data showed up to approximately 35% reduction in standardized uptake value (SUV) and approximately 24% reduction in standardized uptake value ratio (SUVR) in affected brain regions, marking the third indication where foralumab has demonstrated reduced inflammation on PET scans. This is a positive clinical catalyst for a pre-revenue biotech with no approved disease-modifying treatments for MSA, but the data is from only two patients and remains early-stage.
Key Facts
- Initial quantitative PET imaging results from first two MSA patients in Phase 2 trial showed up to ~35% reduction in SUV and ~24% reduction in SUVR in affected brain regions.
- This is the third indication (after non-active secondary progressive MS and moderate Alzheimer's) showing marked reduction in inflammation on PET scans with intranasal foralumab.
- MSA is a rare, progressive neurodegenerative disorder with no approved disease-modifying treatments.
- Reductions were observed in basal ganglia and cerebellar white matter, regions known to be involved in MSA.
- Tiziana plans to continue evaluating intranasal foralumab in additional patients to further validate these early findings.
Financial Impact
No financial data provided; clinical-stage biotech with no revenue.
Risk Factors
- Data is from only two patients — very early and may not replicate in larger cohorts.
- No placebo control in this initial analysis; results are open-label.
- Clinical-stage biotech with no approved products or revenue; reliant on financing.
- Regulatory and commercial path for MSA is uncertain given the lack of approved therapies and complex trial endpoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-056213 |
| Document: ea029079901ex99-1.htm | 0001213900-26-056213 |
| Document: 0001213900-26-056213-index-headers.html | 0001213900-26-056213 |
| Document: 0001213900-26-056213-index.html | 0001213900-26-056213 |
| Document: 0001213900-26-056213.txt | 0001213900-26-056213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (−12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (+12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8823 (−15.97%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8823 (−20.51%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8823 (−9.97%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8823 (−2.47%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8823 (−23.28%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8823 (−9.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers